Drug Profile
AZD 2836
Alternative Names: A-831; AZD2836Latest Information Update: 22 Sep 2015
Price :
$50
*
At a glance
- Originator Arrow Therapeutics
- Class Antivirals; Small molecules
- Mechanism of Action Hepatitis C virus NS 5 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Hepatitis C
Most Recent Events
- 26 Sep 2008 Arrow Therapeutics terminates a phase I/II trial in Hepatitis C in UK and New Zealand
- 31 Aug 2007 Phase-I/II clinical trials in Hepatitis C in New Zealand (PO)
- 31 Aug 2007 Phase-I/II clinical trials in Hepatitis C in United Kingdom (PO)